GoodRx (GDRX) Q2 2026 earnings review
The Pivot is Working, But the Core Continues to Erode
GoodRx's deliberate strategy to cannibalize its legacy discount card business in favor of manufacturer partnerships and condition-specific subscriptions is showing faster-than-expected results. While total Q2 revenue was roughly flat (-1% YoY) at $200.4M, the underlying mix shift is massive: Pharma Direct surged 76% and Subscriptions grew 39%, heavily offsetting a 26% collapse in Prescription Transactions (PTR). This successful momentum led management to raise full-year revenue and Adjusted EBITDA guidance. However, the transition comes at a cost to profitability. Net income dropped 33% YoY to $8.5M, and Adjusted EBITDA margins compressed to 31.8% as the company trades legacy, high-margin transaction fees for long-term direct-to-consumer durability.
🐂 Bull Case
Pharma Direct and Subscriptions now make up 45% of total revenue, up from 27% a year ago. As these segments continue accelerating (76% and 39% YoY growth, respectively), they will soon overtake the declining legacy business, driving a return to consolidated top-line growth.
Management originally forecasted a bleak 2026 with revenues dropping to $750-$780M. After strong Q1 and Q2 execution, they have raised the target to $790-$805M, effectively returning to flat-to-positive growth relative to FY25.
🐻 Bear Case
Monthly Active Consumers (MACs) fell to 5.0 million in Q2. Management previously claimed the user base had stabilized at 5.3 million in Q1. This breakdown in the floor suggests the core marketplace is deteriorating faster than projected.
The pivot is expensive. Adjusted EBITDA margin dropped 240 basis points YoY as GoodRx accepts lower unit economics from retail partners and shifts marketing spend to build its new condition-specific subscriptions.
⚖️ Verdict: ⚪
Neutral to Bullish. The structural shift away from a declining, PBM-reliant discount model toward a durable, B2B/D2C access platform is undeniably working. If the growth lines continue their current trajectory, 2027 could mark a return to significant, durable expansion—assuming the legacy business doesn't completely crater before the crossover point.
Key Themes
Pharma Direct Accelerates Through D2C Tailwinds
Pharma Direct revenue accelerated significantly, growing 76% YoY to $61.6M. GoodRx is successfully positioning itself as the 'access infrastructure' for pharmaceutical manufacturers shifting toward cash-pay and direct-to-consumer models. The company now hosts over 125 manufacturer-sponsored programs. This growth is heavily tethered to the GLP-1 boom (Wegovy, Zepbound), where GoodRx is acting as the primary digital storefront for patients facing insurance coverage gaps.
Condition-Specific Subscriptions Revive Growth
The Subscription segment reversed its historical decline, accelerating to 39% YoY growth ($28.5M). Total subscription plans expanded to 764,000, up from 668,000 a year ago. The turnaround is entirely driven by the shift away from general savings plans toward condition-specific offerings, particularly 'GoodRx for weight loss', which has shown highly efficient customer acquisition costs and deeper consumer engagement.
MAC Contradiction: The Floor Broke
A critical red flag emerged in the user data: Monthly Active Consumers (MACs) dropped to 5.0 million. In the prior quarter (Q1), MACs held at 5.3 million for two consecutive quarters, leading management to explicitly state they had modeled the metric to 'flatten out' for the rest of the year. This 300,000 sequential drop contradicts the stabilization narrative and implies the legacy marketplace leak has not been plugged.
Margin Squeeze from Unit Economics Reset
The strategic pivot comes with a structural margin penalty. Adjusted EBITDA margin fell from 34.2% in 25Q2 to 31.8% in 26Q2. Management is deliberately accepting lower fees on core prescription transactions to appease retail pharmacy partners and secure long-term durability, whilst shifting marketing investments toward new subscription offerings. This 'bidirectional flow of dollars' strategy supports retailers but compresses GoodRx's bottom line.
Macro Tailwinds: Insurance Gaps & Policy
The macro environment is serving as a strong catalyst. Elevated out-of-pocket costs, higher Medicare Part D premiums, and Medicaid eligibility changes are driving consumers toward cash-pay options. Concurrently, government-led price transparency initiatives like 'TrumpRx' act as a validation of GoodRx's model, forcing manufacturers to establish direct-to-consumer pricing programs that GoodRx is uniquely positioned to fulfill.
Other KPIs
A standout metric this quarter. Despite Net Income falling 33% to $8.5M, operating cash flow surged 63% YoY from $49.6M. This massive divergence is largely driven by working capital dynamics, specifically a $53.6M favorable change in accounts receivable, proving the underlying cash generation of the business remains highly robust despite P&L margin compression.
Decelerating aggressively. The 26% YoY decline was driven by lower unit economics, the deliberate shift of marketing away from this segment, and compounding effects from prior retail pharmacy disruptions. The rate of decline has worsened from -3% in Q2'25 and -24% in Q1'26.
Guidance
Accelerating significantly vs prior expectations. Management raised the full-year outlook from the $765-$785M range given in Q1 (and original $750-$780M given in Q4'25). The new midpoint of $797.5M implies the company will match or slightly exceed FY25's total of $796.9M, effectively erasing the previously forecasted 'transition year' top-line recession.
Reversing the bearish outlook. Initially, management set an EBITDA floor of 'at least $230M' to allow room for investment. The new range implies margin stabilization in the second half of the year, though it will still represent a decline from the $270.5M delivered in FY25.
Key Questions
The MAC Contradiction
In the Q1 call, you indicated that Monthly Active Consumers had stabilized at 5.3 million and were modeled to 'flatten out' for the rest of the year. In Q2, MACs fell significantly to 5.0 million. What specifically caused this floor to break, and what is the new expected baseline for the legacy marketplace?
Marketing Efficiency in Subscriptions
With Subscription revenue up 39% and plans growing nicely to 764k, you mentioned directing marketing spend away from the general brand and toward condition-specific offerings. Can you quantify the Customer Acquisition Cost (CAC) trends for these new subscribers compared to your historical marketplace users?
PTR Unit Economics Floor
You've intentionally reset unit economics in the core PTR business to build more durable relationships with pharmacy partners. As PTR revenue falls 26% YoY, are we nearing the bottom of these fee concessions, or should we expect further proactive margin compression in late 2026 and 2027?